Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809100 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL808762 | 0.91 | HTR2A (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL27653549 | 0.91 | HTR2A (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL808764 | 0.88 | CASR (0.42) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL809120 | 0.86 | HTR2A (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL809112 | 0.86 | CASR (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6UGT2B7 | |
| SCHEMBL809143 | 0.84 | TAAR1 (0.47) | — | |
| SCHEMBL27653553 | 0.84 | HTR2A (0.41) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL809144 | 0.84 | TAAR1 (0.47) | — | |
| SCHEMBL27653552 | 0.84 | HTR2A (0.41) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958940-B1 | CONDENSATION REACTION BY METAL CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110098479-A1 | CONDENSATION REACTION BY METAL CATALYST | MASHIMA KAZUSHI | 2011-04-28 | — | — | US | disclosed |
| US-7888513-B2 | Condensation reaction by metal catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | OSAKA UNIVERSITY (JP) | 2009-08-06 | — | — | US | disclosed |
| CN-100436406-C | Process for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL CO (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1958940-A1 | CONDENSATION REACTION BY METAL CATALYST | Takasago International Corporation (JP) | 2008-08-20 | — | — | EP | disclosed |
| CN-101125833-A | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| CN-1898193-A | Method for producing optically active bisamidealcohol compound | SUMITOMO CHEMICAL CO (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098479-A1 | CONDENSATION REACTION BY METAL CATALYST | C9, CBR3, C1R | SLC6A2 4602/4885SLC6A4 3420/4885SLC6A3 4490/4885 |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | SLC6A2 2607/4885SLC6A4 2470/4885SLC6A3 1876/4885 |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | C9, CBR3, C1R | SLC6A2 4602/4885SLC6A4 3420/4885SLC6A3 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.